Objective To study the effect of gastrin receptor antagonist on large intestine cancer patients with liver metastatic. Methods Thirty eight patients received chemotherapy in control group, in therapy group 46 patients received chemotherapy and gastrin receptor antagonist pruglumide 1 200 mg/day. Follow-up was done each month in two groups. Results In control group, liver metastatic cancer increased 8.1±2.2 cm， 1-year mortality was 55.3% (21/38), and in therapy group, liver metastatic cancer increased 3.5±1.2 cm, the mortality was 21.7% (10/46), which was significantly lower than that in control group (Ｐ＜0.01).Conclusion Gastrin receptor antagonist can delay cancer proliferation, prolong survival time and decrease death rate of colon cancer patients with liver metastasis.